Prakt. lékáren. 2007; 3(6): 275-279

Účinnost chřipkových vakcín

RNDr. Marek Petráš
Specialista v oboru vakcinologie, Praha

Světová zdravotnická organizace (SZO) vždy v únoru každého roku vydává doporučení k použití výrobních vakcinačních chřipkových kmenů pro následující chřipkovou sezónu. Toto doporučení vychází z analýzy dat poskytovaných více než stovkou laboratoří po celém světě, které se účastní sledování globálního výskytu chřipky. Během roku se chřipkové viry třídí a vybírají se chřipkové virové izoláty, jenž se zasílají do tří světových center SZO: ve Spojených státech, Anglii a Austrálii. Tímto způsobem se monitorují genetické změny cirkulujících chřipkových kmenů. Doporučené vakcinační kmeny vycházejí nejen z virologických a epidemiologických dat, ale i z možností stávajících výrobních vakcinačních kmenů, které poskytnout odpovídající imunitní odpověď vůči předpokládanému chřipkovému kmeni.

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráš M. Účinnost chřipkových vakcín. Praktické lékárenství. 2007;3(6):275-279.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Al-Khayatt R, Jennings R, Potter CW. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J. Hyg. Camb., 92, 301, 1984. Go to original source... Go to PubMed...
    2. Bellelli E, Bracchi Vv Tanzi Mx. Applicazione alle ricerche epidemiologi-che sull'influenza della reazione di immunoemolisi radiale. Ig. Mod., 72, 343, 1979.
    3. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133-1137. Go to original source... Go to PubMed...
    4. Blumberg EA, Albano C, Pruett T et al. Immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302. Go to original source... Go to PubMed...
    5. Boyce TG, Gruber WC, Coleman-Dockery SD et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 2000; 18: 82-88. Go to original source... Go to PubMed...
    6. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and costbenefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284: 1655-1663. Go to original source... Go to PubMed...
    7. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997; 39: 408-414. Go to original source... Go to PubMed...
    8. Carman WF, Elder AG, Wallace LA et al. Effects of infuenza vaccination of healthcare workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355: 93-97. Go to original source... Go to PubMed...
    9. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149: 1113-1117. Go to original source... Go to PubMed...
    10. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991; 163: 300-304. Go to original source... Go to PubMed...
    11. Crawford CR, Faiza Mukhlis FA, Jennings R et al. Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions. Vaccine 1984; 2: 193-198. Go to original source... Go to PubMed...
    12. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997; 8: 776-779. Go to original source... Go to PubMed...
    13. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine. 2003 Oct 1; 21(27-30): 4234-4237. Go to original source... Go to PubMed...
    14. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. Efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebocontrolled trial. JAMA 1994; 272: 1661-1665. Go to original source... Go to PubMed...
    15. Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. Vaccine 1994; 12: 139-141. Go to original source... Go to PubMed...
    16. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. Efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-527. Go to original source... Go to PubMed...
    17. Hak E, Nordin J, Wei F et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35: 370-377. Go to original source... Go to PubMed...
    18. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991; 145: 445-448. Go to original source... Go to PubMed...
    19. Hirota Y, Kaji M, Ide S et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962-967. Go to original source... Go to PubMed...
    20. Jennings R, Smith TL, Spencer RC et al. Inactivated influenza virus vaccines in man: A comparative study of subunit and split vaccines using two methods for assessment of antibody responses. Vaccine 1984; 2: 75-80. Go to original source... Go to PubMed...
    21. King JC, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998; 177: 1394-1397. Go to original source... Go to PubMed...
    22. La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine-1978. Rev Infect Dis 1983; 5: 723-736. Go to original source... Go to PubMed...
    23. McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackley RC. Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr Soc 1990; 38: 652-658. Go to original source... Go to PubMed...
    24. Monto AS, Ohmit SE. Effectiveness evaluation of inactivated influenza vaccines: Methods and results. In Brown LE, Hampson AW, Webster RG (eds). Options for the Control of Influenza III. Amsterdam, Elsevier Science BV, 1996; pp.93-96.
    25. Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-952. Go to original source... Go to PubMed...
    26. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and coldadapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001; 20: 733-740. Go to original source... Go to PubMed...
    27. Neuzil KM, Reed GW, Mitchel EF et al. Impact of infuenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148: 1094-1102. Go to original source... Go to PubMed...
    28. Nichol KL, Lind A, Margolis KL et al. Effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-893. Go to original source... Go to PubMed...
    29. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998; 158: 1769-1776. Go to original source... Go to PubMed...
    30. Nordin J, Mullooly J, Poblete S et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001; 184: 665-670. Go to original source... Go to PubMed...
    31. Oxford JS, Schild GC, Potter CW, Jennings R. Specificity of the antihaemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. J Hyg (Lond) 1979; 82: 51-61. Go to original source... Go to PubMed...
    32. Oxford Js, Yetts R, Schild GC. <<Quantitation and analysis of the specificity of postimmunization antibodies to influenza B viruses using single radial haemolysis>>. J. Hyg. Camb., 1982; 88, 325. Go to original source... Go to PubMed...
    33. Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996; 98: 196-200. Go to original source... Go to PubMed...
    34. Patriarca PA, Weber JA, Parker RA et al. Risk factors for outbreaks of influenza in nursing homes: a case-control study. Am J Epidemiol 1986; 124: 114-119. Go to original source... Go to PubMed...
    35. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35: 69-75. Go to original source... Go to PubMed...
    36. Potter J, Stott DJ, Roberts MA et al. Infuenza vaccination of health care workers in longterm-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175: 1-6. Go to original source... Go to PubMed...
    37. Russel SM, Mc Cahon D, Beare AS. <<A single radial haemolysis tecnique for the measurement of influenza antibody>>. J. Gen. Virol., 27, 1, 1975. Go to original source...
    38. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994; 272: 1122-1126. Go to original source...
    39. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines. II. Immunogenicity and original sin in humans. J Infect Dis 1976; 134: 48-58. Go to original source... Go to PubMed...
    40. Weekly epidemiological rekord, 12 JULY 2002, 77th YEAR, No. 28, 2002; 77, 229-240.
    41. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908-913. Go to original source... Go to PubMed...
    42. Zangwill KM, Droge J, Mendelman P et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001; 20: 740-746. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.